Silica Gel Column Chromatography: How It Works and How to Choose the Silica

Published: Source: Silica Raw Materials News Section: Silica Raw Materials

📌 Key Takeaways

  • Topic: BET Surface Area of Silica: Measurement Method and Typical Values by Grade
  • Keywords: silica for wafer polishing
  • Published: 2026-11-20 02:52:53
  • Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Wet granulation is the most frequently used technique to process MSNs, because of the many possibilities inherent in it [ 106 ]. Conventional wet granulation is well-suited for the granulation of silica nanocarriers, but several things should be considered during implementation. There are two possible sequences: first, the drug loading, followed by the granulation of the loaded carriers [ 104 ], or the opposite way, the granulation of the empty carriers, then loading the drug into the prepared granules. In the first case, during the planning and implementation of the process, special attention must be paid to the critical process parameters to steer clear of premature drug release [ 104 ]. In general, it can be noted that as little moisture as possible should be used during granulation, consequently decreasing the risk of premature drug release. Still, simultaneously, moisture adequate to produce the desired agglomeration must be made sure [ 104 ]. The risk of premature drug release depends to a certain extent on the chemical structure of the API and the carrier. Szewczyk and Prokopowicz developed doxycycline-loaded MSN pellets with prolonged release kinetics [ 40 ]. First, the drug was loaded into the pores, and then pellets were produced from the loaded mesoporous material with other excipients by wet extrusion and spheronization. For comparison, traditional doxycycline pellets were also prepared. This study demonstrated the importance of utilizing mesoporous carriers for the delayed or sustained release of water-soluble drugs. Pelletization was a successful method to reduce the initial burst release of doxycycline; twice the release time was observed compared to traditional pellets [ 40 ]. Szewczyk et al. developed another DDS loaded with an antibiotic compound (cefazolin) for the treatment of osteomyelitis [ 66 ]. The amine-functionalized MSN was successfully loaded with the drug, and because of the powerful interactions between the negatively charged cefazolin and the positively charged surface of the carrier, a prolonged release of 5 days was observed, which made sure a longer antibacterial influence than with classic pellets. This was proven by the microbiological activity assays of the pellets against S. aureus culture [ 66 ]. These results are promising in antibiotic or anticancer therapy, where therapeutic concentration is needed for a longer period [ 40, 66 ]. A comparable outcome was presented in another publication about metformin-containing MSN pellets with prolonged release kinetics [ 85 ]. After drug loading, pellets were formed with the mixture of the preloaded carriers and chitosan solution, and then the pellets were coated with five layers of chitosan. Since the stomach is not considered the best possible absorption surface for metformin, it is advisable to delay the release until conditions in the intestines are ideal for maximum bioavailability. Chitosan plays an important role in this formulation; it slows down and delays the metformin release and offers delayed and prolonged release kinetics, thereby preventing speedy blood level peaks after application [ 85 ]. On the contrary, Wang et al. published a post on MSN pellets filled with poorly water-soluble carbamazepine, and they observed better oral bioavailability compared to commercially available tablets based on in vivo analysis performed on dogs [ 86 ]. In vitro dissolution studies confirmed a raised dissolution rate compared to crystalline carbamazepine due to the amorphous state of the drug within the pores. This immediate-release pellet formulation allows for a reduction in the drug dose, sustaining the same clinical influence [ 86 ].

Silica SDS: Key Hazards, Handling and Storage Information Explained

Spherical Silica Manufacturer: Key Capabilities, Purity Control and Selection Criteria
Even though MSNs can usually be recognized as secure products, their use during therapy may cause side impacts in the body [ 1, 2, 29 ]. Due to their small size and large surface area, they may tend to accumulate in the body, or certain organs (liver, spleen, kidney, lung) and may even be toxic in higher concentrations, which is a clear disadvantage [ 1, 4, 27 ]. The silanol groups (Si-OH) on their surface can interact with the phospholipid layer of the cell membrane, thereby causing cell lysis or, in extreme cases, hemolysis [ 4, 8 ]. In severe cases, the lack of hemocompatibility can also cause issues [ 2 ]. Overall, indications of cytotoxicity, haemotoxicity, and genotoxicity were also found [ 4, 8 ]. That is why the biocompatibility of all comparable preparations must be strictly controlled [ 2, 4, 27 ]. The physicochemical features (particle size, particle morphology, surface chemistry, pore structure, etc.) of nanocarriers also have a major impact on toxicity [ 2, 4, 8, 30 ]. Additionally, further attention must be paid to the biological influences of their decomposition products, because they may also cause unwanted side influences [ 1 ]. The breakdown of silica nanoparticles in the body can take up to a few days. The opening hydration is followed by hydrolysis, and, in the end, they are excreted in the urine in the form of silicic acid [ 1 ]. Nevertheless, the literature is contradictory in this regard [ 31 ]. Some experiments show no considerable cytotoxic effect [ 18, 31 ], while other experiments say otherwise [ 23, 32 ]. For example, an in vitro study was performed with multiple concentrations, surfaces, and particle sizes (60 nm, 100 nm, 300 nm) of MSNs, with an exposure time of 72 h [ 18 ]. This study shown no significant cytotoxic influence in any of the cell lines tested (human cervical (HeLA), epithelial lung (A549), and glioblastoma (U251)) [ 18 ]. Ismail et al. investigated the cytotoxic effect of silica nanoparticles in vivo in mouse models [ 33 ]. Amorphous silica nanoparticles were administered to the animals orally, at a dose of 150 mg/kg/day, for 3 months. Based on these mouse models, no toxic effects were detected under sub-chronic treatment of the nanoparticles [ 31 ]. In another study, particle size (15 nm, 60 nm, 200 nm) dependent impact was observed on cellular viability in all four cell lines tested (THP-1 derived macrophages, A549 epithelial cells, HaCaT keratinocytes, and NRK-52E kidney cells) [ 23 ]. Smaller particles caused notable toxicity on each cell line, after the exposure time of 24 h, in contrast to the larger particles, which demonstrated no cytotoxic impact [ 23 ]. A comparable outcome has been published to verify the toxic characteristic of mesoporous silica. In this in vitro study, the researchers investigated the effect of MSNs with an average size of 7 nm on cell viability at three different concentrations. After 72 h of exposure, only the highest concentration (62.5 µg/mL) caused a substantial decrease in cell viability of human lung fibroblast cells. This toxicity occurred in a time- and dose-dependent manner [ 32 ]. In an in vivo mouse model, MacCuaig et al. presented coating-dependent impacts after repeated intravenous administration of MSNs. Chitosan-coated MSNs induced minor organ changes and were the most biocompatible. Uncoated and especially PEG-coated MSNs (especially 2K PEG) moderately augmented pre-existing vascular or organ lesions, implying that PEGylation has the potential to augment chronic risks, while chitosan enables safer long-term use [ 34 ]. An in vitro study of Barguilla et al. exposed epithelial lung cells to bare, PEG-functionalized, or galacto-oligosaccharide-functionalized MSNs for eight weeks. There was no reported long-term DNA damage, but malignant-like alterations like anchorage-independent growth, boosted migration/invasion, and secretome-facilitated tumor promotion were triggered by PEG- and GAL-functionalized MSNs. Naked MSNs did not cause such alterations and were determined to be safer [ 35 ]. Coating, on the whole, exerts a significant impact on the safety of MSNs. Uncoated MSNs are relatively innocuous; the most biocompatible coatings were achieved with chitosan, but PEG and carbohydrate functionalization can be dangerous in the long run, from vascular toxicity in vivo to tumor-promoting activity in vitro [ 34, 35 ].
Grace Syloid: Silica Product Range for Coatings, Pharma and Food
Silica Supplier Europe: Major Producers, Regulations and Sourcing Options
Project No. TKP2021-EGA-32 was implemented with support provided by the Ministry of Culture and Innovation of Hungary through the National Research, Development, and Innovation Fund, financed under the TKP2021-EGA funding scheme.
Silica for Epoxy Molding Compound (EMC): Spherical Silica Specs and Selection

What Is Hydrophilic Silica? Properties, Grades and Applications

What is silica (SiO₂)?

silica quote

What is the difference between fumed silica and precipitated silica?

surface treated silica

What drives silica raw material prices?

PPG Hi-Sil 65. Mal A., Prabhuraj R., Malhotra R., Valvi S.K., Ingle A., Srivastava R., De A., Bandyopadhyaya R. pH-responsive sustained delivery of doxorubicin employing aminated and PEGylated mesoporous silica nanoparticles leads to boosted antitumor efficacy in pre-clinical orthotopic breast cancer model. J. Drug Deliv. Sci. Technol. 2022;77:103800. doi: 10.1016/j.jddst.2022.103800. [ DOI ] [ Google Scholar ]

Cite this article: Silica Raw Materials News. "How to Buy Silica Powder: Grade Selection, Supplier Checks and Ordering Tips ." Published 2026-11-20 02:52:53. /news/article.html
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.